The knowledge that the biology is more complex and heterogeneous in CRC than in melanoma is supported by several preclinical data suggesting that, differently from melanoma, CRC cell lines express high levels of activated EGFR, which convey a reactivation of MAPK pathway following BRAF inhibition [77,78]. The gene discussed is BRAF; the disease is colorectal carcinoma.